← All trials
NCT07013565
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 7, 2025
- Primary completion
- Jul 1, 2029
- Completion date
- Jul 1, 2030
- First posted
- Jun 10, 2025
- Last posted
- Oct 21, 2025
- Enrollment
- 20
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- New York Medical CollegeLead sponsor
- New York Medical CollegeOfficial
- Medical College of WisconsinCollaborator
- University of Alabama, BirminghamCollaborator
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Michigan State UniversityCollaborator
- University of UtahCollaborator
- Ohio State UniversityCollaborator
- Ohio State UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
- University of California, IrvineCollaborator
- University of PennsylvaniaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.